Literature DB >> 29803615

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience.

Bolanle Gbadamosi1, Daniel Ezekwudo2, Sanjog Bastola3, Ishmael Jaiyesimi2.   

Abstract

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous malignancy with diverse genetic abnormalities, clinical presentations, and outcomes. Known predictive and prognostic factors in AML include age, performance status, comorbidities, cytogenetics, and molecular mutations. Identifying prognostic and predictive factors can inform the choice of induction therapy and outcomes prediction. PATIENTS AND METHODS: A retrospective review was performed of 137 adult AML patients from 2010 to 2015. Predictors of complete remission (CR) and overall survival (OS) were determined for patients treated with 3+7 (3 days of anthracycline and 7 days of cytarabine) or hypomethylating agent. Variables associated with CR or OS were assessed using univariate Cox regression and a multivariate Cox model.
RESULTS: The average age was 65 years and 91 patients (66%), sample size is 137 patients had primary AML. Patients in the 3+7 induction group were younger, had a higher bone marrow blast percentage, and more de novo AML compared with those in the hypomethylating agent group (P < .001, P < .001, P = .005, respectively). Univariate logistic regression for CR showed a significant association between age (P < .001), choice of induction (P < .001), and monosomy (P = .015), although only induction with 3+7 (P < .001) and absence of monosomy (P = .042) remained significant in multivariate analysis. Univariate Cox regression indicated that age (P = .003), AML status (de novo or secondary; P = .0277), choice of induction (P = .030), and monosomy (P = .010) had a significant association with OS. Only younger age (P = .018) and absence of monosomy (P = .022) were predictive of OS in multivariate Cox analysis.
CONCLUSION: Positive predictors of CR in adult AML include absence of monosomy and induction treatment with 3+7; whereas positive predictors of OS are younger age and absence of monosomy. Published by Elsevier Inc.

Entities:  

Keywords:  Complete remission; Cytogenetics; Induction; Molecular; Overall survival

Mesh:

Substances:

Year:  2018        PMID: 29803615     DOI: 10.1016/j.clml.2018.05.005

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  4 in total

1.  Impact of HOXB4 and PRDM16 Gene Expressions on Prognosis and Treatment Response in Acute Myeloid Leukemia Patients.

Authors:  Yomna M El-Meligui; Naglaa M Hassan; Amira B Kassem; Nora A Gouda; Marwa Mohanad; Manal A Hamouda; Ahmad Salahuddin
Journal:  Pharmgenomics Pers Med       Date:  2022-06-25

2.  Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy.

Authors:  Dwi Wahyunianto Hadisantoso; Dody Ranuhardy; Wulyo Rajabto; Aulia Rizka; Lyana Setiawan; Ikhwan Rinaldi; Arif Mansjoer; Erni Juwita Nelwan; Hamzah Shatri
Journal:  F1000Res       Date:  2022-05-05

3.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

Review 4.  Management of Acute Myeloid Leukemia (AML) in Older Patients.

Authors:  Maya Abdallah; Zhuoer Xie; Audrey Ready; Dharmini Manogna; Jason H Mendler; Kah Poh Loh
Journal:  Curr Oncol Rep       Date:  2020-07-28       Impact factor: 5.945

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.